Comparative Evaluation of Quality Attributes and In Vitro Dissolution Profile Similarity of Metformin Hydrochloride 500 mg Tablets Marketed in Sudan: Implications for Bioequivalence and Generic Interchangeability

In the world of medicine, a pill is more than just a small, solid object; it is a carefully engineered delivery system designed to release a specific chemical into the body at the right moment. For a drug to work, it must first survive the journey from the factory to the pharmacy shelf, and then, once swallowed, it must break apart and dissolve in the stomach or intestines to become available for absorption. This process is not automatic. The way a tablet is compressed, the ingredients mixed with the active medicine, and the conditions under which it is stored can all change how quickly and completely the drug dissolves. If a tablet dissolves too slowly, the body may not get enough of the medicine to treat an illness. If it dissolves too fast, the drug might pass through the system before it can do its job. This is why scientists and regulators do not just check if a pill contains the correct amount of medicine; they also test how that medicine behaves when it meets fluid, ensuring that a generic version of a drug performs just like the original brand-name product.

This reality is critical for millions of people living with type 2 diabetes, a condition where the body struggles to manage blood sugar levels. The most common first-line treatment for this condition is a drug called metformin hydrochloride. In Sudan, where the prevalence of diabetes is high, patients rely heavily on this medication, often switching between different brands available in local pharmacies. While these brands all claim to contain the same 500-milligram dose of the drug, they are made by different manufacturers, some locally and some imported. The question researchers asked was simple but vital: do all these different brands actually work the same way? To find out, a team of scientists from universities in Sudan, Uganda, and Saudi Arabia purchased five of the most common brands of metformin tablets sold in Khartoum. They treated the original brand, imported from France, as the standard to measure against, while the other four brands, two from India and Saudi Arabia and two made in Sudan, served as the test subjects.

The researchers began by examining the physical nature of the tablets. They looked at their shape, color, and size, and then subjected them to a series of rigorous tests that mimic the stresses a pill might face. They checked if the tablets were too soft and would crumble in the bottle, or too hard and might not break apart in the stomach. They weighed individual tablets to ensure every single one in a batch was nearly identical in mass, and they measured how long it took for the tablets to fall apart in warm water. All five brands passed these basic physical checks. They were all the correct shape, they did not crumble easily, and they all broke apart within fifteen minutes, which is the standard requirement for this type of medication.

However, the story changed when the scientists looked deeper into the chemical content and how the drug dissolved. They measured the actual amount of active medicine in each tablet. While four of the brands contained the expected amount of metformin, one brand, labeled as Brand B, contained significantly less than the label claimed. This was the first sign that not all tablets were created equal. But the most revealing part of the study came from watching how the drugs dissolved over time. The researchers placed tablets from each brand into a fluid that simulates the environment of the human body and measured how much medicine was released at ten-minute intervals for ninety minutes.

The results showed a clear divide. The original brand and three of the generic brands dissolved at a steady, reliable pace, releasing at least 80 percent of their medicine within thirty minutes. This is the benchmark for a drug to be considered effective and interchangeable. Two of the generic brands, one imported from Saudi Arabia and one made locally in Sudan, followed the dissolution pattern of the original brand so closely that they could be considered perfect substitutes. However, the brand that had failed the chemical content test also failed the dissolution test, releasing only about 71 percent of its medicine in the required time. This meant that a patient taking this specific brand might not receive enough drug to control their blood sugar effectively.

Interestingly, another brand, while containing the correct amount of medicine and dissolving quickly, did so too fast. It released its drug much more rapidly than the original brand, creating a different pattern of release. While this might sound like a good thing, the researchers noted that a drug that dissolves too quickly can behave differently in the body than the one it is meant to replace. Just as a car engine that revs too high might not run as smoothly as one tuned to a specific rhythm, a drug that releases too fast may not provide the same steady therapeutic effect. This finding highlighted a crucial point: passing a basic quality check does not guarantee that a generic drug is truly equivalent to the original.

The study concluded that while most of the metformin brands available in Sudan were of high quality and could be safely swapped with the original product, at least one brand was substandard and another was too different in its behavior to be considered a perfect match. The researchers emphasized that relying solely on simple checks is not enough to ensure patient safety. Instead, they recommended that regulators require more detailed testing, specifically looking at how the drug dissolves over time, before allowing different brands to be used interchangeably. By doing so, they argued, healthcare systems could ensure that every patient, regardless of which brand they are prescribed, receives the exact same therapeutic benefit, keeping their blood sugar levels stable and their health secure.